StockWatch
·
Pharmaceutical Preparations
Quarterly ResultMay 13, 2026, 06:09 AM

Azitra Q1 Net Loss $(3.93)M; Cash $10.05M; Raises $10.4M in Series A

AI Summary

Azitra, Inc. reported an increased net loss of $(3.93) million for the first quarter of 2026, compared to $(3.07) million in the same period last year. Despite the loss, the company significantly bolstered its liquidity, with cash and cash equivalents rising to $10.05 million and total stockholders' equity reaching $10.48 million. This improvement was largely driven by $10.38 million in net proceeds from a private placement and $10.4 million from a Series A Preferred Stock Offering. The company also disclosed a going concern warning and recorded $623,532 in impairment expenses for deferred patent costs.

Key Highlights

  • Net loss increased to $(3.93) million for Q1 2026 from $(3.07) million in Q1 2025.
  • Net loss per share improved to $(0.25) for Q1 2026 from $(1.55) in Q1 2025.
  • Cash and cash equivalents surged to $10.05 million as of March 31, 2026, from $2.07 million at December 31, 2025.
  • Total stockholders' equity increased to $10.48 million as of March 31, 2026, from $3.80 million at December 31, 2025.
  • Net cash provided by financing activities was $10.50 million in Q1 2026, up from $1.75 million in Q1 2025.
  • Received $10.38 million net proceeds from a private placement and $10.4 million net proceeds from a Series A Preferred Stock Offering.
  • Recorded $623,532 in impairment expenses for deferred patent costs during Q1 2026.
  • Company faces substantial doubt about its ability to continue as a going concern.